Finance entity
markets is the sole category represented across all 1 tracked stories. ICOTYDE is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Protagonist Therapeutics, Inc. appears in 1 tracked Finance story from September 8, 2026. The tracked stories average 2 original sources each.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. ICOTYDE is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Protagonist Therapeutics, Inc. appears in 1 tracked Finance story from September 8, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics has authorized up to $300 million in buybacks, funded by an $849.5 million cash position and upcoming Takeda collaboration payments. Investors will watch how aggressively management repurchases shares and whether the program signals undervaluation or a lack of higher-return investments.
Protagonist Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
